

## P&T Motion History Quick Relief Asthma Drugs

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<p><u>Short-acting beta agonists (SABA):</u> albuterol levalbuterol pirbuterol</p> <p><b>Short Acting Anticholinergics</b> ipratropium bromide</p> <p><u>Combination drugs:</u> <b>albuterol/budesonide</b> ipratropium bromide/ albuterol</p>	<p>After considering the evidence of safety, efficacy and special populations of using short acting beta agonists for quick relief of Asthma, I move that albuterol, and levalbuterol are safe and efficacious. The Washington Preferred Drug List must include a nebulizer and metered dosed formulation. The short acting beta agonists can be subject to therapeutic interchange in the Washington preferred drug list for the quick relief of Asthma.</p> <p>After considering the evidence of safety, efficacy and special populations of using short acting beta agonists for quick relief of Asthma, I move that pirbuterol is not considered safe and efficacious for quick relief of Asthma.</p> <p>After considering the evidence of safety, efficacy and special populations of albuterol/budesonide combination for quick relief of Asthma, I move that albuterol/budesonide is safe and efficacious, and be added to the Washington Preferred Drug List for the quick relief of asthma.</p> <p>All delivery systems and indications will be included for all drugs.</p> <p>Motion: Flynn 2<sup>nd</sup>: Hudson</p>	June 26, 2024	N/A	No	Passed unanimous

**Bold** = new this update  
Grey = Not included in the reports  
7/2/2024

**P&T Motion History**  
**Quick Relief Asthma Drugs**



**Bold** = new this update  
Grey = Not included in the reports  
**7/2/2024**

**P&T Motion History  
Quick Relief Asthma Drugs**

--	--	--	--	--	--

**Bold** = new this update  
Grey = Not included in the reports  
**7/2/2024**